Kura Oncology Inc (KURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kura Oncology Inc (KURA) has a cash flow conversion efficiency ratio of -1.292x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.55 Million) by net assets ($48.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Kura Oncology Inc worth for the company's overall valuation and market capitalisation.
Kura Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Kura Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kura Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kura Oncology Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Kura Oncology Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Matrix Design Co. Ltd. A
SHE:301365
|
N/A |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866
|
0.149x |
|
Shenzhen SEG Co Ltd
SHE:000058
|
0.110x |
|
DATATEC LTD (UNSP.ADR)/2
F:DTT0
|
N/A |
|
Max Zipper Co Ltd
TWO:8932
|
0.110x |
|
Caisse Régionale de Crédit Agricole Mutuel de Paris et d-Ile-de-France
PA:CAF
|
0.025x |
|
Monex S.A.B. de C.V
MX:MONEXB
|
-1.308x |
|
Ningbo Exciton Technology Co Ltd
SHE:300566
|
0.052x |
Annual Cash Flow Conversion Efficiency for Kura Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Kura Oncology Inc from 2009 to 2025. View KURA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $174.13 Million | $-64.06 Million | -0.368x | -213.29% |
| 2024-12-31 | $413.64 Million | $134.32 Million | 0.325x | +203.35% |
| 2023-12-31 | $397.27 Million | $-124.82 Million | -0.314x | -19.98% |
| 2022-12-31 | $420.28 Million | $-110.06 Million | -0.262x | -26.90% |
| 2021-12-31 | $506.61 Million | $-104.55 Million | -0.206x | -80.55% |
| 2020-12-31 | $610.90 Million | $-69.83 Million | -0.114x | +54.33% |
| 2019-12-31 | $218.78 Million | $-54.76 Million | -0.250x | +17.18% |
| 2018-12-31 | $160.99 Million | $-48.66 Million | -0.302x | +15.13% |
| 2017-12-31 | $79.86 Million | $-28.44 Million | -0.356x | +20.10% |
| 2016-12-31 | $56.88 Million | $-25.35 Million | -0.446x | -104.14% |
| 2015-12-31 | $82.10 Million | $-17.93 Million | -0.218x | -29526.93% |
| 2014-12-31 | $-3.43 Million | $-2.55K | 0.001x | -99.62% |
| 2013-12-31 | $-123.96K | $-24.42K | 0.197x | -17.18% |
| 2012-12-31 | $-95.35K | $-22.68K | 0.238x | -15.92% |
| 2011-12-31 | $-68.03K | $-19.24K | 0.283x | -39.75% |
| 2010-12-31 | $-40.99K | $-19.24K | 0.469x | -59.14% |
| 2009-12-31 | $-18.60K | $-21.37K | 1.149x | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more